Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Letai

Showing results (51-60 of 182) with videos related to

Pageof 19
Sort By:
The Journal of Cell Biology|December 2, 2009
MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterpartsJoslyn K Brunelle, Jeremy Ryan, Derek Yecies, et al.
Cell Death and Differentiation|January 6, 2025
Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependenciesJulie A MacDonald, Gary A Bradshaw, Fleur Jochems, et al.
Cell Death and Differentiation|July 24, 2019
BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimeticsMariana Villalobos-Ortiz, Jeremy Ryan, Thelma N Mashaka, et al.
Cancer Cell|August 19, 2007
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agentsJing Deng, Nicole Carlson, Kunihiko Takeyama, et al.
Elife|June 9, 2017
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1Justin M Jenson, Jeremy A Ryan, Robert A Grant, et al.
ACS Chemical Biology|July 24, 2014
Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cellsGlenna Wink Foight, Jeremy A Ryan, Stefano V Gullá, et al.
Journal of Molecular Biology|December 3, 2014
Potent and specific peptide inhibitors of human pro-survival protein Bcl-xLSanjib Dutta, Jeremy Ryan, T Scott Chen, et al.
Blood|December 7, 2007
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemiaVictoria Del Gaizo Moore, Krysta D Schlis, Stephen E Sallan, et al.
Nature|December 12, 2003
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1Joseph T Opferman, Anthony Letai, Caroline Beard, et al.
Cancer Cell|September 21, 2002
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeuticsAnthony Letai, Michael C Bassik, Loren D Walensky, et al.
Pageof 19

Showing results (51-60 of 182) with videos related to

Sort By:
Pageof 19
The Journal of Cell Biology|December 2, 2009
MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterpartsJoslyn K Brunelle, Jeremy Ryan, Derek Yecies, et al.
Cell Death and Differentiation|January 6, 2025
Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependenciesJulie A MacDonald, Gary A Bradshaw, Fleur Jochems, et al.
Cell Death and Differentiation|July 24, 2019
BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimeticsMariana Villalobos-Ortiz, Jeremy Ryan, Thelma N Mashaka, et al.
Cancer Cell|August 19, 2007
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agentsJing Deng, Nicole Carlson, Kunihiko Takeyama, et al.
Elife|June 9, 2017
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1Justin M Jenson, Jeremy A Ryan, Robert A Grant, et al.
ACS Chemical Biology|July 24, 2014
Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cellsGlenna Wink Foight, Jeremy A Ryan, Stefano V Gullá, et al.
Journal of Molecular Biology|December 3, 2014
Potent and specific peptide inhibitors of human pro-survival protein Bcl-xLSanjib Dutta, Jeremy Ryan, T Scott Chen, et al.
Blood|December 7, 2007
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemiaVictoria Del Gaizo Moore, Krysta D Schlis, Stephen E Sallan, et al.
Nature|December 12, 2003
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1Joseph T Opferman, Anthony Letai, Caroline Beard, et al.
Cancer Cell|September 21, 2002
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeuticsAnthony Letai, Michael C Bassik, Loren D Walensky, et al.
Pageof 19